Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
This is a comment on Pharmaceuticals 2010, 3(1), 146-157 .

Pharmaceuticals 2010, 3(6), 1887-1891; doi:10.3390/ph3061887
Commentary

In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)

1,2,* , 2
 and 1,3
Received: 29 April 2010; in revised form: 31 May 2010 / Accepted: 9 June 2010 / Published: 10 June 2010
(This article belongs to the Special Issue Monoclonal Antibody)
View Full-Text   |   Download PDF [146 KB, uploaded 10 June 2010]
Abstract: To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that — besides the Glycart and the Biowa approach to generate de-fucosylated antibodies — innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile.
Keywords: therapeutic antibodies; glyco-modified IgG; ADCC; CDC; Fc -γRIII therapeutic antibodies; glyco-modified IgG; ADCC; CDC; Fc -γRIII
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nechansky, A.; Koller, I.; Kircheis, R. In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157). Pharmaceuticals 2010, 3, 1887-1891.

AMA Style

Nechansky A, Koller I, Kircheis R. In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157). Pharmaceuticals. 2010; 3(6):1887-1891.

Chicago/Turabian Style

Nechansky, Andreas; Koller, Iris; Kircheis, Ralf. 2010. "In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)." Pharmaceuticals 3, no. 6: 1887-1891.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert